Featured Research

from universities, journals, and other organizations

Eyes may provide a look into multiple sclerosis progression

Date:
December 26, 2012
Source:
American Academy of Neurology (AAN)
Summary:
New research suggests that thinning of a layer of the retina in the eyes may show how fast multiple sclerosis (MS) is progressing in people with the disease.

New research suggests that thinning of a layer of the retina in the eyes may show how fast multiple sclerosis (MS) is progressing in people with the disease. The study is published in the Jan. 1, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology.

"This study suggests that retinal thinning, measured by in-office eye scans, called OCT, may occur at higher rates in people with earlier and more active MS," said Robert Bermel, MD, with the Cleveland Clinic Mellen Center for MS and a member of the American Academy of Neurology, who wrote an accompanying editorial.

For the study, 164 people with MS from the Johns Hopkins MS Center, including 59 who had no disease activity, underwent eye scans that measured thinning of a portion of their retinas every six months for an average of 21 months. Participants were also given MRI brain scans at the start of the study and yearly.

The study found that people with MS relapses had 42 percent faster thinning than people with MS who had no relapses. People with MS who had inflammatory lesions called gadolinium-enhancing lesions experienced 54 percent faster thinning and those with new T2 lesions had 36 percent faster thinning than MS patients without these features of MRI activity.

People whose level of disability worsened during the study experienced 37 percent more thinning than those who had no changes in their level of disability, and those who had the disease less than five years showed 43 percent faster thinning than those who had the disease more than five years.

"As more therapies are developed to slow the progression of MS, testing retinal thinning in the eyes may be helpful in evaluating how effective those therapies are," said study author Peter Calabresi, MD, with Johns Hopkins University School of Medicine in Baltimore and a Fellow of the American Academy of Neurology.

The study was supported by the National Multiple Sclerosis Society, the National Eye Institute and Braxton Debbie Angela Dillon and Skip Donor Advisor Fund.


Story Source:

The above story is based on materials provided by American Academy of Neurology (AAN). Note: Materials may be edited for content and length.


Journal References:

  1. J. N. Ratchford, S. Saidha, E. S. Sotirchos, J. A. Oh, M. A. Seigo, C. Eckstein, M. K. Durbin, J. D. Oakley, S. A. Meyer, A. Conger, T. C. Frohman, S. D. Newsome, L. J. Balcer, E. M. Frohman, P. A. Calabresi. Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. Neurology, 2012; 80 (1): 47 DOI: 10.1212/WNL.0b013e31827b1a1c
  2. R. A. Bermel, M. Inglese. Neurodegeneration and inflammation in MS: The eye teaches us about the storm. Neurology, 2012; 80 (1): 19 DOI: 10.1212/WNL.0b013e31827b1b6c

Cite This Page:

American Academy of Neurology (AAN). "Eyes may provide a look into multiple sclerosis progression." ScienceDaily. ScienceDaily, 26 December 2012. <www.sciencedaily.com/releases/2012/12/121226080340.htm>.
American Academy of Neurology (AAN). (2012, December 26). Eyes may provide a look into multiple sclerosis progression. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2012/12/121226080340.htm
American Academy of Neurology (AAN). "Eyes may provide a look into multiple sclerosis progression." ScienceDaily. www.sciencedaily.com/releases/2012/12/121226080340.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins